Drug strategy blocks a leading driver of cancer
Using a new strategy, researchers from UC San Francisco (home of the UCSF Helen Diller Family Comprehensive Cancer Center) have succeeded in making small molecules that irreversibly target a mutant form of the protein RAS, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer, according to the researchers. When tested on human lung cancer cells grown in culture, the molecules efficiently killed the RAS-driven cancer cells.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.